Allopurinol use leading to xanthine nephrolithiasis in pediatric tumor lysis syndrome: a case series
- PMID: 38842722
- DOI: 10.1007/s00467-024-06413-6
Allopurinol use leading to xanthine nephrolithiasis in pediatric tumor lysis syndrome: a case series
Abstract
Tumor lysis syndrome (TLS) is a life-threatening metabolic disorder caused by massive tumor lysis. Allopurinol, a xanthine oxidase inhibitor, is initiated during chemotherapy to prevent hyperuricemia and subsequent acute kidney injury (AKI). We report two cases of xanthine nephrolithiasis during TLS in newly diagnosed hematologic malignancy patients receiving prophylactic allopurinol. Allopurinol use likely promoted xanthine crystallization, stone formation, and AKI.
Keywords: Acute kidney injury; Nephrolithiasis; Pediatrics; Tumor lysis syndrome; Xanthine oxidase inhibitors.
© 2024. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
References
-
- Cheuk DK, Chiang AK, Chan GC et al (2017) Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev 3:Cd006945 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
